1 Choi JY, "The efficacy of lamivudine in Korean patients with chronic hepatitis B" 11 : 25-30, 2005
2 Lai CL, "Telbivudine(LDT) vs. lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial" 42 : 748A-, 2005
3 Bridges E, "Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity" 44 : 147-, 2006
4 "Seroprevalence of hepatitis B virus among health care workers in Korea" 21 : 58-62, 2006
5 "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level" 295 : 65-73, 2006
6 "Natural history and prognostic factors for chronic hepatitis type B" (venta f) : 294-298,
7 Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B" 125 : 1714-1722, 2003
8 "Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B" 334 : 1422-1427, 1996
9 "Lamivudine for patients with chronic hepatitis B and advanced liver disease" 351 : 1521-1531, 2004
10 "High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection" 19 : 670-675, 2004
1 Choi JY, "The efficacy of lamivudine in Korean patients with chronic hepatitis B" 11 : 25-30, 2005
2 Lai CL, "Telbivudine(LDT) vs. lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial" 42 : 748A-, 2005
3 Bridges E, "Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity" 44 : 147-, 2006
4 "Seroprevalence of hepatitis B virus among health care workers in Korea" 21 : 58-62, 2006
5 "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level" 295 : 65-73, 2006
6 "Natural history and prognostic factors for chronic hepatitis type B" (venta f) : 294-298,
7 Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B" 125 : 1714-1722, 2003
8 "Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B" 334 : 1422-1427, 1996
9 "Lamivudine for patients with chronic hepatitis B and advanced liver disease" 351 : 1521-1531, 2004
10 "High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection" 19 : 670-675, 2004
11 Chang TT, "Four years of lamivudine treatment in Chinese patients with chronic hepatitis B" 19 : 1276-1282, 2004
12 Leung NW, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy" 33 : 1527-1532, 2001
13 "Epidemiology and natural history of hepatitis B" 25 : 3-8, 2005
14 Liaw YF, "Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group" 119 : 172-180, 2000
15 Lok ASF, "Chronic hepatitis B" 45 : 507-538, 2007
16 "Antiviral beta-L-nucleosides specific for hepatitis B virus infection" 12 : 119-129, 2001
17 Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update" 4 : 936-962, 2006
18 Lai CL, "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group" 339 : 61-68, 1998
19 Lai CL, "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B" 129 : 528-536, 2005
국립중앙도서관 "우편 복사 서비스"로 연결 됩니다.
KCI
KISS
